Repotrectinib and Vanzacaftor: Interaction Details

Brand names
Repotrectinib
Augtyro
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Vanzacaftor

We don't have a separate drug information page for Vanzacaftor. The FDA's drug directory lists it as part of Alyftrek (vanzacaftor, tezacaftor and deutivacaftor). Have a question about Vanzacaftor? Ask a pharmacist, free →

What Happens When You Take Repotrectinib With Vanzacaftor

What can happen when they are taken together (rated Major)

Reduced vanzacaftor exposure and reduced of vanzacaftor

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Using vanzacaftor together with strong or moderate is not recommended, because these agents may lower vanzacaftor exposure and thereby diminish its efficacy. A drug interaction study evaluated the vanzacaftor/tezacaftor/deutivacaftor combination (20/100/250 mg once daily) given with rifAMPin 600 mg once daily, a strong CYP3A . Under these conditions, vanzacaftor fell significantly by 18% and its by 22%, while deutivacaftor AUC decreased by 10% and its Cmax by 20%.1

The Repotrectinib and Vanzacaftor Interaction, Explained

Repotrectinib (a cancer medicine for certain lung and other tumors) can speed up the way your liver breaks down vanzacaftor, one of the medicines in the cystic fibrosis combination Alyftrek. With more of it cleared, you may have less vanzacaftor in your body, and it may not work as well. Doctors generally advise against using these together.

Please keep taking both as prescribed and do not stop or change anything on your own. Talk with your pharmacist or doctor, who can review your options and decide whether the doses may need to be adjusted and individualized, and whether your team should monitor you more closely.

Mechanism: Repotrectinib is a (moderate to strong by labeling, with PXR-mediated ), which may increase CYP3A-mediated of vanzacaftor and lower its exposure. Vanzacaftor is not a , so the effect is reduced exposure and reduced .

  • Magnitude: Not studied with repotrectinib. With rifampin 600 mg daily (strong inducer), vanzacaftor fell 18% and 22%; deutivacaftor AUC fell 10% and Cmax 20%.
  • Onset: Unspecified. Evidence: probable.
  • Management: with strong or moderate CYP3A is not recommended. Consider alternatives where feasible; if the combination is unavoidable, individualize therapy and monitor CF clinical response closely.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Repotrectinib and Vanzacaftor Interact

The likely mechanism

of -mediated of vanzacaftor

In short: Repotrectinib speeds up CYP3A, an enzyme that breaks down vanzacaftor, so vanzacaftor can be cleared faster.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Lowers Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Repotrectinib and Vanzacaftor Interaction

The documented advice is that vanzacaftor should not generally be combined with like repotrectinib, because lower vanzacaftor levels may reduce how well it works.

  • Keep taking both medicines as prescribed until your care team tells you otherwise.
  • Tell your pharmacist and prescribers (both your cancer and cystic fibrosis teams) that you take both.
  • Your team may review whether another option fits, or individualize your doses and monitor you more closely.
  • Report any worsening of cystic fibrosis symptoms, such as more cough, breathing trouble, or reduced lung function.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Repotrectinib or Vanzacaftor need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: ALYFTREK oral tablets, vanzacaftor, tezacaftor, and deutivacaftor oral tablets

    In a drug interaction study, administration of the vanzacaftor/tezacaftor/deutivacaftor combination (20/100/250 mg once daily) with rifAMPin 600 mg once daily, a strong , significantly lowered the of vanzacaftor by 18% and its by 22%. The same also decreased the AUC of deutivacaftor by 10% and its Cmax by 20%.1

Repotrectinib and Vanzacaftor: Common Questions

How serious is the Repotrectinib and Vanzacaftor interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Repotrectinib and Vanzacaftor interaction managed?

The documented advice is that vanzacaftor should not generally be combined with like repotrectinib, because lower vanzacaftor levels may reduce how well it works. Keep taking both medicines as prescribed until your care team tells you otherwise. Tell your pharmacist and prescribers (both your cancer and cystic fibrosis teams) that you take both. Your team may review whether another… Management is individual — always follow your own care team's guidance.

Does taking Repotrectinib and Vanzacaftor at different times of day help?

No. Taking them at different times of day does not prevent this one. Repotrectinib speeds up , an enzyme that breaks down vanzacaftor, so vanzacaftor can be cleared faster. That change lasts while repotrectinib is being taken and can continue for a while after the last dose.

Your pharmacist or prescriber can tell you how they will manage it.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Repotrectinib and Vanzacaftor Interaction

Ask in your own words about taking Repotrectinib and Vanzacaftor together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: ALYFTREK(R) oral tablets, vanzacaftor, tezacaftor, and deutivacaftor oral tablets. Vertex Pharmaceuticals Incorporated (per FDA), Boston, MA, 2024. DailyMed
Was this write-up helpful?

Other Serious Interactions of Repotrectinib and Vanzacaftor

Also serious with Repotrectinib

Also serious with Vanzacaftor

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Repotrectinib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.